BioMarin Pharmaceutical Inc.
BioMarin Announces Prosensa Therapeutics B.V. Changes Name to BioMarin Nederland B.V.
DGAP-News: BioMarin Pharmaceutical Inc. 2015-04-28 / 08:00 --------------------------------------------------------------------- SAN RAFAEL, Calif., 2015-04-28 08:00 CEST (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Prosensa Therapeutics B.V., a BioMarin company, changed its name to BioMarin Nederland B.V. This name change reflects the further integration of Prosensa into BioMarin. BioMarin acquired Prosensa on Jan. 15, 2015. BioMarin maintains operations at the former Prosensa headquarters, based in Leiden, The Netherlands and has integrated personnel from that office into the company. 'We are pleased that the integration of Prosensa employees into the BioMarin family is going smoothly. We share a common purpose of delivering therapies that will make a meaningful difference to patients with rare genetic diseases,' said Scott Clarke, Site Leader, BioMarin Nederland. 'Together, we are working to bring treatments to boys with Duchenne muscular dystrophy.' About Duchenne muscular dystrophy Duchenne muscular dystrophy (DMD) is a severely debilitating childhood neuromuscular disease that affects up to 1 in 3,500 live male births. This rare disease is caused by mutations in the dystrophin gene, resulting in the absence or defect of the dystrophin protein. As a result, patients suffer from progressive loss of muscle strength, often rendering them wheelchair-bound before the age of 12. Respiratory and cardiac muscle can also be affected by the disease and most patients die in early adulthood due to respiratory and cardiac failure. About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release. CONTACT: Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451 News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-04-28 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: BioMarin Pharmaceutical Inc. United States ISIN: US09061G1013 End of News DGAP News-Service --------------------------------------------------------------------- 349401 2015-04-28
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden